Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/19/23
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023GlobeNewsWire • 10/13/23
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/11/23
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)GlobeNewsWire • 09/26/23
Travere Therapeutics: Tanking On Confirmatory Trial Failure For Kidney Therapy - Is There Hope?Seeking Alpha • 09/22/23
Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-LowInvestors Business Daily • 09/21/23
Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trialMarket Watch • 09/21/23
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, IrbesartanGlobeNewsWire • 09/21/23
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum PharmaceuticalsGlobeNewsWire • 09/05/23
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere TherapeuticsBusiness Wire • 09/05/23
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare ConferenceGlobeNewsWire • 08/31/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/25/23
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023GlobeNewsWire • 08/24/23
Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/04/23
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 08/03/23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere TherapeuticsBusiness Wire • 07/17/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/07/23